Latest Insider Transactions at Talaris Therapeutics, Inc. (TALS)
This section provides a real-time view of insider transactions for Talaris Therapeutics, Inc. (TALS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Talaris Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Talaris Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2025
|
Sandeep Chidambar Kulkarni CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
7,000
-100.0%
|
-
|
|
Oct 28
2025
|
Sandeep Chidambar Kulkarni CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,387
-100.0%
|
-
|
|
Oct 28
2025
|
Sandeep Chidambar Kulkarni CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
724,664
-95.98%
|
-
|
|
Oct 28
2025
|
Ryan F. Robinson CFO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,366
-100.0%
|
-
|
|
Oct 28
2025
|
W Bradford Middlekauff CBO, GC and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,213
-100.0%
|
-
|
|
Oct 28
2025
|
W Bradford Middlekauff CBO, GC and Secretary |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
60,988
-88.13%
|
-
|
|
Oct 28
2025
|
Susan Dana Jones Chief Technology Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,152
-100.0%
|
-
|
|
Oct 28
2025
|
Susan Dana Jones Chief Technology Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
19,782
-86.26%
|
-
|
|
Oct 28
2025
|
Kevin Bruce Johnson Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,046
-100.0%
|
-
|
|
Oct 28
2025
|
Kevin Bruce Johnson Chief Regulatory Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
40,538
-78.59%
|
-
|
|
Oct 28
2025
|
Caley Castelein |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
431,939
-100.0%
|
-
|
|
Oct 28
2025
|
Caley Castelein |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
515,997
-100.0%
|
-
|
|
Oct 28
2025
|
Aaron Kantoff |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
88,281
-100.0%
|
-
|
|
Oct 28
2025
|
Mark Mcdade |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
741,691
-100.0%
|
-
|
|
Oct 28
2025
|
Mark Mcdade |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
518
-100.0%
|
-
|
|
Oct 28
2025
|
Sapna Srivastava |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
518
-100.0%
|
-
|
|
Oct 28
2025
|
Parvinder Thiara |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
83,782
-100.0%
|
-
|
|
Oct 24
2025
|
Aaron Kantoff |
SELL
Bona fide gift
|
Direct |
5,000
-5.36%
|
-
|
|
Oct 22
2025
|
Sandeep Chidambar Kulkarni CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,316
+3.24%
|
$177,212
$7.9 P/Share
|
|
Oct 22
2025
|
Ryan F. Robinson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,366
+50.0%
|
$186,758
$13.92 P/Share
|
|
Oct 15
2025
|
Caley Castelein |
SELL
Bona fide gift
|
Direct |
522
-0.1%
|
-
|
|
Oct 15
2025
|
Kevin Bruce Johnson Chief Regulatory Officer |
SELL
Bona fide gift
|
Direct |
6,250
-10.81%
|
-
|
|
Sep 05
2025
|
Aaron Kantoff |
BUY
Exercise of conversion of derivative security
|
Direct |
47,890
+20.48%
|
$191,560
$4.8 P/Share
|
|
Aug 21
2024
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Indirect |
1,779
+20.26%
|
$24,906
$14.85 P/Share
|
|
Aug 16
2024
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Indirect |
5,221
+50.0%
|
$67,873
$13.79 P/Share
|
|
Jan 29
2024
|
Mark Mcdade |
BUY
Open market or private purchase
|
Indirect |
100,000
+18.23%
|
$3,200,000
$32.5 P/Share
|
|
Nov 17
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+0.55%
|
$64,000
$16.99 P/Share
|
|
Nov 17
2023
|
Parvinder Thiara |
BUY
Open market or private purchase
|
Direct |
1,000
+1.18%
|
$17,000
$17.31 P/Share
|
|
Oct 27
2023
|
Caley Castelein |
BUY
Open market or private purchase
|
Direct |
15,800
+2.97%
|
$221,200
$14.55 P/Share
|
|
Oct 26
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.68%
|
$60,000
$12.25 P/Share
|
|
Oct 25
2023
|
Caley Castelein |
BUY
Open market or private purchase
|
Direct |
4,200
+0.83%
|
$50,400
$12.07 P/Share
|
|
Oct 25
2023
|
Parvinder Thiara |
BUY
Open market or private purchase
|
Direct |
2,000
+2.36%
|
$24,000
$12.12 P/Share
|
|
Oct 24
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Direct |
4,650
+0.64%
|
$46,500
$10.68 P/Share
|
|
Oct 24
2023
|
Aaron Kantoff |
BUY
Open market or private purchase
|
Direct |
7,500
+14.18%
|
$82,500
$11.86 P/Share
|
|
Oct 24
2023
|
Parvinder Thiara |
BUY
Open market or private purchase
|
Direct |
5,000
+5.83%
|
$50,000
$10.66 P/Share
|
|
Oct 19
2023
|
Sapna Srivastava |
BUY
Grant, award, or other acquisition
|
Direct |
518
+50.0%
|
-
|
|
Oct 19
2023
|
Parvinder Thiara |
BUY
Grant, award, or other acquisition
|
Direct |
75,782
+50.0%
|
-
|
|
Oct 19
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Grant, award, or other acquisition
|
Direct |
716,085
+50.0%
|
-
|
|
Oct 19
2023
|
Mark Mcdade |
BUY
Grant, award, or other acquisition
|
Direct |
518
+50.0%
|
-
|
|
Oct 19
2023
|
Mark Mcdade |
BUY
Grant, award, or other acquisition
|
Indirect |
348,431
+50.0%
|
-
|
|
Oct 19
2023
|
W Bradford Middlekauff CBO, GC and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
69,201
+50.0%
|
-
|
|
Oct 19
2023
|
Caley Castelein |
BUY
Grant, award, or other acquisition
|
Indirect |
458,039
+50.0%
|
-
|
|
Oct 19
2023
|
Caley Castelein |
BUY
Grant, award, or other acquisition
|
Direct |
496,519
+50.0%
|
-
|
|
Oct 19
2023
|
Yung H. Chyung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,836
+50.0%
|
-
|
|
Oct 19
2023
|
Kevin Bruce Johnson Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,834
+50.0%
|
-
|
|
Oct 19
2023
|
Susan Dana Jones Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,934
+50.0%
|
-
|
|
Oct 19
2023
|
Aaron Kantoff |
BUY
Grant, award, or other acquisition
|
Direct |
37,891
+50.0%
|
-
|
|
Jul 03
2023
|
Mary Kay Fenton Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,946
-15.98%
|
$38,838
$3.08 P/Share
|
|
Jul 03
2023
|
Scott Requadt |
SELL
Payment of exercise price or tax liability
|
Direct |
11,786
-2.0%
|
$35,358
$3.08 P/Share
|
|
Jun 14
2023
|
Suzanne Ildstad Director |
SELL
Open market or private sale
|
Direct |
12,942
-0.34%
|
$25,884
$2.49 P/Share
|